Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2019
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis ; volume:24 ; number:1 ; day:18 ; month:11 ; year:2021 ; pages:91 ; date:1.2022
Pediatric drugs ; 24, Heft 1 (18.11.2021), 91, 1.2022
- Creator
-
Blair, Hannah A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40272-021-00483-x
- URN
-
urn:nbn:de:101:1-2022042407073250802920
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Blair, Hannah A.
- SpringerLink (Online service)
Other Objects (12)
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Secukinumab (Plaque-Psoriasis) : Addendum zum Auftrag A17-08
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry
Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Secukinumab (Plaque-Psoriasis) : Addendum zum Auftrag A17-08
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry
Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Secukinumab (Plaque-Psoriasis) : Addendum zum Auftrag A17-08
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry